In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B-cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib. The patient tolerated the addition of dasatinib with combination therapy and remained in remission for over nine months until his recurrence. Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B-cell precursor ALL.

Original languageEnglish (US)
Pages (from-to)576-579
Number of pages4
JournalPediatric Blood and Cancer
Volume59
Issue number3
DOIs
StatePublished - Sep 2012

Fingerprint

Gene Rearrangement
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Lymphoid Precursor Cells
Stem Cells
Therapeutics
Transplants
Recurrence
Genes
In Vitro Techniques
Dasatinib

Keywords

  • ALL
  • Dasatinib
  • E2A-HLF

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

@article{2a288f1db25a498db4d52b134efc36ca,
title = "In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia",
abstract = "Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B-cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib. The patient tolerated the addition of dasatinib with combination therapy and remained in remission for over nine months until his recurrence. Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B-cell precursor ALL.",
keywords = "ALL, Dasatinib, E2A-HLF",
author = "Glover, {Jason M.} and Marc Loriaux and Jeffrey Tyner and Brian Druker and Bill Chang",
year = "2012",
month = "9",
doi = "10.1002/pbc.23383",
language = "English (US)",
volume = "59",
pages = "576--579",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia

AU - Glover, Jason M.

AU - Loriaux, Marc

AU - Tyner, Jeffrey

AU - Druker, Brian

AU - Chang, Bill

PY - 2012/9

Y1 - 2012/9

N2 - Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B-cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib. The patient tolerated the addition of dasatinib with combination therapy and remained in remission for over nine months until his recurrence. Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B-cell precursor ALL.

AB - Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B-cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib. The patient tolerated the addition of dasatinib with combination therapy and remained in remission for over nine months until his recurrence. Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B-cell precursor ALL.

KW - ALL

KW - Dasatinib

KW - E2A-HLF

UR - http://www.scopus.com/inward/record.url?scp=84863859105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863859105&partnerID=8YFLogxK

U2 - 10.1002/pbc.23383

DO - 10.1002/pbc.23383

M3 - Article

C2 - 22038978

AN - SCOPUS:84863859105

VL - 59

SP - 576

EP - 579

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -